Showing 4131-4140 of 6036 results for "".
- Oertli Receives FDA 510(k) Clearance for Faros Surgical Systemhttps://modernod.com/news/oertli-instrumente-ag-achieves-milestone-with-fda-510k-clearance-for-faros-surgical-system/2482371/Oertli Instrumente announced it has received FDA 510(k) clearance for the Faros anterior cataract surgery system. According to a company news release, the Faros system offers a compact design and rapid operational readiness, requiring minimal space in operating rooms. It
- AbbVie Launches Refresh Tears PF and Refresh Relieva PF Xtrahttps://modernod.com/news/abbvie-launches-refresh-tears-pf-and-refresh-relieva-pf-xtra/2482369/AbbVie has introduced two new preservative-free (PF) lubricant eye drop products─Refresh Tears PF and Refresh Relieva PF Xtra. According to AbbVie, the new products contain several new features: Multidose Bottle Design: The bottles
- Bausch + Lomb Acquires Diagnostic Company Trukera Medicalhttps://modernod.com/news/bausch-lomb-acquires-diagnostic-company-trukera-medical/2482368/Bausch + Lomb announced it has acquired US-based privately held ophthalmic medical diagnostic company Trukera Medical. Financial terms of the deal were not disclosed. An affiliate of B+L acquired Trukera from its private equity owner, AccelMed Partners, and other shareholders. 
- EssilorLuxottica Acquires Majority Stake in Heidelberg Engineeringhttps://modernod.com/news/essilorluxottica-acquires-majority-stake-in-heidelberg-engineering/2482362/Optical industry giant EssilorLuxottica announced it has reached a deal to acquire an 80% stake in Germany-based Heidelberg Engineering. Financial terms of the deal were not disclosed. Founded by Dr. Gerhard Zinser and Christoph Schoess in 1990, Heidelberg is a prov
- Heidelberg Engineering Introduces Faster OCT Angiography with Spectralis Shift Technologyhttps://modernod.com/news/heidelberg-engineering-introduces-faster-oct-angiography-with-spectralis-shift-technology/2482359/Heidelberg Engineering has received FDA clearance of the Spectralis OCTA Module with Shift technology, which is designed to reduce acquisition time by 50%.[1] The preset OCTA speed of 125 kHz helps streamline workflow, enhance clinical e
- Claes H. Dohlman, MD, Cornea Research Pioneer and Visionary, Passes Away at 101https://modernod.com/news/claes-h-dohlman-md-cornea-research-pioneer-and-visionary-passes-away-at-101/2482356/Cornea Research Pioneer Claes H. Dohlman, MD, PhD, professor of Ophthalmology, Emeritus, and former Chief and Chair of the Department of Ophthalmology at Mass Eye and Ear and Harvard Medical School (HMS), passed away at the age of 101 on July 14, 2024, Mass Eye and Ear announced on Monday.
- Mount Sinai Ophthalmologists Present New Research at ASRShttps://modernod.com/news/mount-sinai-ophthalmologists-present-new-research-at-asrs/2482355/Ophthalmologists from New York Eye and Ear Infirmary of Mount Sinai in New York City have prepared the following research for the ASRS annual meeting in Stockholm, Sweden, July 17-20. FOUNDERS AWARD WINNER LECTURE Jammi
- iOR Partners Appoints Lance J. Kugler, MD, to the Role of Strategic Advisory Board Chairmanhttps://modernod.com/news/ior-partners-appoints-lance-j-kugler-md-to-the-role-of-strategic-advisory-board-chairman/2482351/Ophthalmic office-based surgery provider IOR Partners announced that Lance J. Kugler, MD, has been named Chairman of the Strategic Advisory Board. Dr. Kugler opened one of the first OBS suites in 2017 and published a study on the safety of office-based lens surgery in The
- Genentech to Reintroduce Susvimo Ocular Implant for Wet AMDhttps://modernod.com/news/genentech-to-reintroduce-susvimo-for-wet-amd/2482347/Following the end of a voluntary recall, Genentech said it is reintroducing Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of wet age-related macular degeneration (AMD). The decision c
- PharmAbcine Advances Phase 1 Clinical Trial of PMC-403 for nAMDhttps://modernod.com/news/pharmabcine-advances-phase-1-clinical-trial-of-pmc-403-for-namd/2482343/PharmAbcine, Inc., a South Korea-based clinical-stage developer of medical therapeutics, announced the Safety Review Committee (SRC) approval of single 3-mg dose for the third cohort in phase 1 clinical trial of PMC-403, the company&rsquo